No connection

Search Results

ICLR vs LLY

ICLR
ICON Public Limited Company
NEUTRAL
Price
$116.50
Market Cap
$9.06B
Sector
Healthcare
AI Confidence
85%
LLY
Eli Lilly and Company
NEUTRAL
Price
$958.65
Market Cap
$858.01B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ICLR
15.7
LLY
41.7
Forward P/E
ICLR
9.49
LLY
22.78
P/B Ratio
ICLR
0.95
LLY
32.33
P/S Ratio
ICLR
1.12
LLY
13.16
EV/EBITDA
ICLR
7.88
LLY
27.08

Profitability

Gross Margin
ICLR
28.16%
LLY
83.04%
Operating Margin
ICLR
12.67%
LLY
44.9%
Profit Margin
ICLR
7.4%
LLY
31.67%
ROE
ICLR
6.27%
LLY
101.16%
ROA
ICLR
4.2%
LLY
19.41%

Growth

Revenue Growth
ICLR
0.6%
LLY
42.6%
Earnings Growth
ICLR
-98.7%
LLY
51.4%

Financial Health

Debt/Equity
ICLR
0.38
LLY
1.65
Current Ratio
ICLR
1.06
LLY
1.58
Quick Ratio
ICLR
1.01
LLY
0.78

Dividends

Dividend Yield
ICLR
--
LLY
0.68%
Payout Ratio
ICLR
0.0%
LLY
26.14%

AI Verdict

ICLR NEUTRAL

ICLR presents a stark contrast between strong deterministic health and deteriorating growth fundamentals. While the Piotroski F-Score of 7/9 indicates a strong financial foundation and the stock trades below its Graham Number ($142.86) and Book Value (P/B 0.95), the recent earnings collapse (-98.7% YoY) is a critical concern. The massive PEG ratio of 19.29 suggests the stock is significantly overvalued relative to its current growth trajectory. Despite analyst 'Buy' recommendations, the technical trend remains bearish and revenue growth has stagnated.

Strengths
Strong Piotroski F-Score (7/9) indicating operational health
Low Debt/Equity ratio (0.38) suggesting conservative leverage
Trading below Graham Number ($142.86) and Book Value (P/B 0.95)
Risks
Catastrophic recent earnings growth decline (-98.7% YoY)
Stagnant revenue growth (0.60% YoY) indicating a lack of expansion
Extreme PEG ratio (19.29) signaling poor growth-to-price alignment
LLY NEUTRAL

LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.

Strengths
Strong profitability (31.7% margin)
Strong revenue growth of 42.6%
Strong ROE of 101.2%
Risks
High valuation with P/E of 41.7
Premium vs Graham Number ($123.85)
Weak financial trend (Piotroski F-Score: 3/9)

Compare Another Pair

ICLR vs LLY: Head-to-Head Comparison

This page compares ICON Public Limited Company (ICLR) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile